These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17169252)

  • 1. Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol.
    Toth PP
    Curr Atheroscler Rep; 2007 Jan; 9(1):81-8. PubMed ID: 17169252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDL as a target in the treatment of atherosclerotic cardiovascular disease.
    Linsel-Nitschke P; Tall AR
    Nat Rev Drug Discov; 2005 Mar; 4(3):193-205. PubMed ID: 15738977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting high-density lipoproteins: update on a promising therapy.
    Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
    Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.
    Lim S; Park YM; Sakuma I; Koh KK
    Int J Cardiol; 2013 Jun; 166(1):8-14. PubMed ID: 22503572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we take high-density lipoprotein cholesterol levels at face value?
    Leite JO; Fernandez ML
    Am J Cardiovasc Drugs; 2010; 10(1):1-3. PubMed ID: 20104929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome.
    Cannon CP
    Clin Cornerstone; 2007; 8 Suppl 6():S14-23. PubMed ID: 17948363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies on HDL: should it be a target biomarker in patients with lipid disorders?
    Nicholls SJ; Andrews J; Duong M
    Curr Vasc Pharmacol; 2014; 12(4):649-52. PubMed ID: 23627977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?
    Escolà-Gil JC; Cedó L; Blanco-Vaca F
    Expert Opin Drug Discov; 2014 Feb; 9(2):119-24. PubMed ID: 24328789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise.
    Zhang B; Kawachi E; Miura S; Uehara Y; Matsunaga A; Kuroki M; Saku K
    Circ J; 2013; 77(11):2651-63. PubMed ID: 24107398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
    Hausenloy DJ; Yellon DM
    Curr Opin Cardiol; 2009 Sep; 24(5):473-82. PubMed ID: 19574922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel HDL-based therapeutic agents.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):18-30. PubMed ID: 22465158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL therapy for cardiovascular diseases: the road to HDL mimetics.
    White CR; Datta G; Zhang Z; Gupta H; Garber DW; Mishra VK; Palgunachari MN; Handattu SP; Chaddha M; Anantharamaiah GM
    Curr Atheroscler Rep; 2008 Oct; 10(5):405-12. PubMed ID: 18706282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
    Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
    J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.